What is Kernicterus?
Kernicterus, also called bilirubin‑induced neurologic dysfunction (BIND), is a rare but serious type of brain damage that occurs when there is a very high level of unconjugated (indirect) bilirubin in the bloodstream of a newborn. The excess bilirubin can cross the immature blood‑brain barrier and deposit in the basal ganglia, thalamus, hippocampus, and brainstem, leading to permanent neurological impairment.
In most cases kernicterus follows severe **neonatal hyperbilirubinemia** (jaundice) that is not recognized or treated promptly. While the condition is uncommon in high‑resource settings, it remains a leading cause of preventable childhood disability worldwide.
Sources: Mayo Clinic; American Academy of Pediatrics (AAP); World Health Organization (WHO)
Common Causes
The underlying factor for kernicterus is an accumulation of unconjugated bilirubin. The following conditions or circumstances increase the risk of such buildup in newborns:
- Hemolytic disease of the newborn (HDN) – especially due to ABO or Rh incompatibility.
- Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency – an inherited enzyme defect that makes red blood cells fragile.
- Hereditary spherocytosis or other red‑cell membrane disorders.
- Crigler‑Najjar syndrome type I – a rare genetic deficiency of the enzyme UGT1A1.
- Breast‑milk jaundice – usually appears after the first week and may persist for weeks.
- Physiologic jaundice of the newborn – common in the first 2–3 days; can become severe in preterm infants.
- Prematurity (<37 weeks gestation) – immature liver enzymes and a more permeable blood‑brain barrier.
- Sepsis or serious bacterial infection – increases bilirubin production and reduces hepatic clearance.
- Maternal factors – such as diabetes, hypertension, or use of certain medications (e.g., sulfonamides) that affect bilirubin metabolism.
- Prolonged or ineffective phototherapy – failure to lower bilirubin levels quickly enough.
Associated Symptoms
Early hyperbilirubinemia typically presents with visible jaundice. When bilirubin levels rise to neurotoxic ranges (>20 mg/dL in term infants, lower in preterm), other clinical clues may appear:
- Extreme lethargy or poor feeding
- High‑pitched cry that may become weak or absent
- Hypotonia (floppy‑baby appearance) progressing to hypertonia or stiffness
- Seizures, especially focal or myoclonic types
- Abnormal eye movements (up‑gaze paresis)
- Hearing loss (often detected later in childhood)
- Movement disorders: choreo‑athetosis, dystonia, or ataxia
- Developmental delays, intellectual disability, or cerebral palsy‑like findings in survivors
These symptoms reflect damage to the basal ganglia and other vulnerable brain regions.
When to See a Doctor
Newborn jaundice is common, but prompt evaluation is crucial when any of the following occur:
- Jaundice visible on the face or chest within the first 24 hours of life.
- Yellowing spreading to the abdomen, thighs, or arms before day 4.
- Infant is lethargic, difficult to wake, or not feeding well.
- Rapid increase in bilirubin levels on serial testing.
- Premature birth, low birth weight, or known hemolytic disease.
- Family history of bilirubin metabolism disorders.
If any of these signs are present, contact a pediatrician or go to the nearest emergency department immediately. Early intervention can prevent irreversible brain injury.
Diagnosis
Diagnosing kernicterus involves confirming severe hyperbilirubinemia and documenting neurological involvement.
1. Laboratory Evaluation
- Total serum bilirubin (TSB): measured via transcutaneous meter or blood draw; values >20 mg/dL (≈340 µmol/L) in term infants raise high concern.
- Direct vs. indirect bilirubin: Kernicterus is linked to *unconjugated* (indirect) bilirubin.
- Complete blood count (CBC) and reticulocyte count: look for hemolysis.
- Coombs (direct antiglobulin) test: detects maternal antibodies.
- G6PD assay, liver function tests, and blood culture if infection is suspected.
2. Clinical Assessment
- Physical exam focusing on skin/eye color, muscle tone, reflexes, and level of consciousness.
- Neurological exam for abnormal eye movements, seizures, or abnormal posturing.
3. Imaging & Ancillary Tests
- Brain MRI: may show hyperintensity in the basal ganglia on T1‑weighted images, supporting the diagnosis.
- Auditory Brainstem Response (ABR) testing: assesses early hearing loss.
- Electroencephalography (EEG): useful if seizures are present.
4. Scoring Tools
The AAP’s hyperbilirubinemia nomogram (Bhutani chart) helps determine treatment thresholds based on age in hours, birth weight, and risk factors.
Treatment Options
Management focuses on rapidly lowering serum bilirubin, protecting the brain, and treating any underlying cause.
Acute Interventions
- Intensive Phototherapy:
- Blue‑light (460–490 nm) from LED or fluorescent lamps.
- Continuous exposure (≥12 h/day) with blankets or pads to increase surface area.
- Exchange transfusion if bilirubin remains >25 mg/dL or neurologic signs appear despite maximal phototherapy.
- Exchange Transfusion:
- Removes bilirubin‑laden blood and replaces it with donor blood.
- Performed in NICU under strict monitoring for complications (electrolyte shifts, infection, thrombocytopenia).
- Intravenous Immunoglobulin (IVIG): May be used in hemolytic disease due to maternal antibodies to reduce ongoing hemolysis.
- Medications:
- Phenobarbital is occasionally used in Crigler‑Najjar type II to induce hepatic enzymes.
Supportive Care
- Maintain adequate hydration and caloric intake – breastfeeding should be encouraged, and supplemental feeds given if needed.
- Monitor temperature, urine output, and weight daily.
- Screen for and treat infections promptly.
Long‑Term Management
- Neurological follow‑up for motor, speech, and cognitive development.
- Early intervention services (physical, occupational, speech therapy).
- Regular audiology assessments – many children develop sensorineural hearing loss.
- Hepatology referral for rare genetic disorders (e.g., Crigler‑Najjar).
Prevention Tips
Because kernicterus is largely preventable, implementing these strategies can drastically reduce risk:
- Early bilirubin screening: Obtain a transcutaneous bilirubin measurement before discharge (usually at 24–48 h for term infants, earlier for preterms).
- Identify high‑risk newborns: Prematurity, ABO/Rh incompatibility, G6PD deficiency, bruising or birth trauma.
- Encourage frequent feeding: 8–12 feeds per 24 h help promote stool output and bilirubin excretion.
- Track weight loss: Neonates should lose <10 % of birth weight in the first 24 h; >10 % warrants evaluation.
- Prompt phototherapy: Initiate at bilirubin levels that meet AAP treatment thresholds.
- Educate parents: Teach how to recognize worsening jaundice (yellowing of abdomen, arms, or legs) and when to call the doctor.
- Genetic counseling: For families with known hereditary bilirubin disorders.
- Neonatal follow‑up: Ensure at least one pediatric visit within 48 h of hospital discharge for all infants.
Emergency Warning Signs
- Newborn appears unusually sleepy, difficult to awaken, or not feeding adequately.
- Rapidly increasing jaundice that spreads to the chest, abdomen, or limbs within a few hours.
- High‑pitched or absent cry; abnormal eye movements (up‑gaze palsy).
- Seizure activity or rhythmic jerking movements.
- Stiff or floppy limbs, especially if tone changes abruptly.
- Any infant under 24 hours old with visible jaundice.
- Known severe hemolytic disease or a bilirubin level above the treatment threshold on a recent lab.
If any of these signs are observed, seek emergency medical care immediately. Prompt treatment can prevent permanent brain injury.